Extra Hep B Vaccine Dose Exceeds Expectations for People With HIV
WASHINGTON — Three doses of hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG; Heplisav-B) notched a perfect mark when it came to seroprotection for people with HIV who had never before been vaccinated against the hepatitis B virus (HBV), early results of a phase III trial showed. At 28 weeks, the three doses yielded […]
Reassuring Data on Two-Dose Hep B Vaccine, Risk of Acute MI
There was no higher risk of heart attack for recipients of the two-dose hepatitis B cytosine phosphoguanine adjuvant vaccine (Heplisav-B) compared to the three-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (Engerix-B), a prospective study found. Among nearly 70,000 adults who received at least one hepatitis B vaccine dose, type 1 acute myocardial infarctions […]